Ablynx Nv (ABLYF) 10.4900 $ABLYF
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW"
GlobeNewswire - Thu Jul 03, 11:07AM CDT
Ablynx [Euronext Brussels: ABLX] announces that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO" took place today and as a result, Ablynx issued 4,908,332 new shares.
What to Watch at Merck, CytRx, and Mylan This Morning
Leo Sun, The Motley Fool - Motley Fool - Mon Feb 03, 8:16AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a closer...
Algeta Appoints Dr Andreas Menrad as Chief Scientific Officer
Marketwire - Mon Aug 19, 12:27AM CDT
Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, is pleased to announce the appointment of Dr Andreas Menrad as Chief Scientific Officer (CSO) and member of the executive management team. In this newly created role, Dr Menrad will be responsible for developing and executing the Company's research strategy, including its Targeted Thorium Conjugate (TTC) platform. He will lead a rapidly growing and highly experienced R&D team. Dr Menrad will report directly to Andrew Kay, Algeta's President & CEO, and takes up his position immediately.
ACTIVAERO'S PARTNER ABLYNX INITIATED PHASE I STUDIES IN RESPIRATORY SYNCYTIAL VIRUS (RSV) USING FAVORITE TECHNOLOGY
Thomson Reuters ONE - Thu Jul 18, 3:11AM CDT
Activaero GmbH / ACTIVAERO'S PARTNER ABLYNX INITIATED PHASE I STUDIES IN RESPIRATORY SYNCYTIAL VIRUS (RSV) USING FAVORITE TECHNOLOGY . Ad hoc announcement according to 15 WpHG. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
Ablynx: Publication in Accordance With Articles 14 and 15 of the Belgian Law of 2 May 2007 on the Publication of Major Shareholdings (the "Transparency Law"
Marketwire - Fri Mar 08, 11:45AM CST
Ablynx (EURONEXT BRUSSELS: ABLX), the biopharmaceutical company focused on the discovery and development of Nanobodies(R), announces today that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO" took place on 5 March 2013 and as a result, Ablynx issued 4,377,919 new shares. In addition, 348,400 new shares were issued that same day as a result of the exercise of 641,800 warrants.
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW"
GlobeNewswire - Thu Jul 03, 11:07AM CDT
Ablynx [Euronext Brussels: ABLX] announces that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO"
took place today and as a result, Ablynx issued 4,908,332 new shares. What to Watch at Merck, CytRx, and Mylan This Morning
Leo Sun, The Motley Fool - Motley Fool - Mon Feb 03, 8:16AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a closer...
Algeta Appoints Dr Andreas Menrad as Chief Scientific Officer
Marketwire - Mon Aug 19, 12:27AM CDT
Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, is pleased to announce the appointment of Dr Andreas Menrad as Chief Scientific Officer (CSO) and member of the executive management team. In this newly created role, Dr Menrad will be responsible for developing and executing the Company's research strategy, including its Targeted Thorium Conjugate (TTC) platform. He will lead a rapidly growing and highly experienced R&D team. Dr Menrad will report directly to Andrew Kay, Algeta's President & CEO, and takes up his position immediately.
ACTIVAERO'S PARTNER ABLYNX INITIATED PHASE I STUDIES IN RESPIRATORY SYNCYTIAL VIRUS (RSV) USING FAVORITE TECHNOLOGY
Thomson Reuters ONE - Thu Jul 18, 3:11AM CDT
Activaero GmbH / ACTIVAERO'S PARTNER ABLYNX INITIATED PHASE I STUDIES IN RESPIRATORY SYNCYTIAL VIRUS (RSV) USING FAVORITE TECHNOLOGY . Ad hoc announcement according to 15 WpHG. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
Ablynx: Publication in Accordance With Articles 14 and 15 of the Belgian Law of 2 May 2007 on the Publication of Major Shareholdings (the "Transparency Law"
Marketwire - Fri Mar 08, 11:45AM CST
Ablynx (EURONEXT BRUSSELS: ABLX), the biopharmaceutical company focused on the discovery and development of Nanobodies(R), announces today that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO"
took place on 5 March 2013 and as a result, Ablynx issued 4,377,919 new shares. In addition, 348,400 new shares were issued that same day as a result of the exercise of 641,800 warrants. 
